URC102

DRUG4 trials

Sponsors

JW Pharmaceutical

Conditions

GoutHealthyHealthy, Renal ImpairmentHyperuricemia

Phase 1

Phase 1 Study of URC102 in Healthy Subjects

CompletedNCT01953497

JW PharmaceuticalHealthy

Start: 2013-05-23End: 2014-07-31Updated: 2017-03-08

Phase 1 Study(Additional) of URC102 in Healthy Subjects

CompletedNCT02524678

JW PharmaceuticalHealthy

Start: 2015-08-05End: 2016-03-28Updated: 2020-02-13

A Safety, PK, PD and Food Effect Study of URC102 in Healthy Adults and Patients With Renal Impairment

CompletedNCT05198778

JW PharmaceuticalHealthy, Renal Impairment

Start: 2021-11-29End: 2022-07-13Updated: 2022-12-06

Phase 2

Study of URC102 to Assess the Safety and Efficacy in Gout Patients

CompletedNCT02557126

JW PharmaceuticalGout, Hyperuricemia

Start: 2015-10-31End: 2016-08-31Updated: 2017-01-10

Related Papers

Efficacy and safety of epaminurad, a potent hURAT1 inhibitor, in patients with gout: a randomized, placebo-controlled, dose-finding study

Arthritis Research & Therapy2025-05-26

OUP accepted manuscript

Lara D. Veeken2019-01-0114 citations